PremiumThe FlyApollomics Inc trading halted, volatility trading pause Apollomics regains compliance with Nasdaq minimum bid rule Apollomics Inc trading resumes PremiumThe FlyApollomics presents Vebreltinib data in patients with NSCLC Apollomics announces preliminary data on vebreltinib Apollomics announces changes in executive leadership team PremiumThe FlyApollomics price target lowered to $5 from $17 at H.C. Wainwright Apollomics reports FY23 EPS ($2.32) vs ($8.44) last year Apollomics appoints Plunkett as CFO 
